Avatar
Bridgesalt9

0 Following 0 Followers
1
On KV, Ramsey SD: Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013, 31(6):794?10. 6. Labelle AJ, Micek ST, Roubinian N, Kollef MH: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008, 36(11):2967?9
1
On KV, Ramsey SD: Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013, 31(6):794?10. 6. Labelle AJ, Micek ST, Roubinian N, Kollef MH: Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008, 36(11):2967?9
1
From the infectious diseases working party of the German Society of Hematology and Oncology. Ann Oncol 2011, 22(5):1019?029. Peacock JE, Herrington DA, Wade JC, Lazarus HM, Reed MD, Sinclair JW, Haverstock DC, Kowalsky SF, Hurd DD, Cushing DA, Harman CP, Donowitz GR: Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A r
1
Enter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005, 41(5):654?59. Bassetti M, Marchetti M, Chakrabarti A, Colizza S, Garnacho-Montero J, Kett DH, Munoz P, Cristini F, Andoniadou A, Viale P, Rocca GD, Roilides E, Sganga G, Walsh TJ, Tascini C, Tumbarello M, Menichetti F, Righi E, Eckmann C,Zafrani and Azoulay BMC I
1
E 2 cm ESR1-positive and ESR2-low, tumor size >2 cm ESR1-positive or ESR2-low or both, tumor size 2 cm ESR1-positive or ESR2-low or both, tumor size >2 cmaDisease-free survival Number 837 199 638 312 525 410 410 378 459 306 332 175 218 147 181 334 386 HR 95 CI P value 0.001 0.59 0.001 0.19 0.007 0.003 0.43 0.001 0.31 0.001 0.34 0.84 0.005 0.66 0.25 0.82 0.73 0.93 0.94 0.76 1.17 0.79 0.68 0.90 0
1
E 2 cm ESR1-positive and ESR2-low, tumor size >2 cm ESR1-positive or ESR2-low or both, tumor size 2 cm ESR1-positive or ESR2-low or both, tumor size >2 cmaDisease-free survival Number 837 199 638 312 525 410 410 378 459 306 332 175 218 147 181 334 386 HR 95 CI P value 0.001 0.59 0.001 0.19 0.007 0.003 0.43 0.001 0.31 0.001 0.34 0.84 0.005 0.66 0.25 0.82 0.73 0.93 0.94 0.76 1.17 0.79 0.68 0.90 0
1
E 2 cm ESR1-positive and ESR2-low, tumor size >2 cm ESR1-positive or ESR2-low or both, tumor size 2 cm ESR1-positive or ESR2-low or both, tumor size >2 cmaDisease-free survival Number 837 199 638 312 525 410 410 378 459 306 332 175 218 147 181 334 386 HR 95 CI P value 0.001 0.59 0.001 0.19 0.007 0.003 0.43 0.001 0.31 0.001 0.34 0.84 0.005 0.66 0.25 0.82 0.73 0.93 0.94 0.76 1.17 0.79 0.68 0.90 0
1
E 2 cm ESR1-positive and ESR2-low, tumor size >2 cm ESR1-positive or ESR2-low or both, tumor size 2 cm ESR1-positive or ESR2-low or both, tumor size >2 cmaDisease-free survival Number 837 199 638 312 525 410 410 378 459 306 332 175 218 147 181 334 386 HR 95 CI P value 0.001 0.59 0.001 0.19 0.007 0.003 0.43 0.001 0.31 0.001 0.34 0.84 0.005 0.66 0.25 0.82 0.73 0.93 0.94 0.76 1.17 0.79 0.68 0.90 0